Skip to main content
OpenTrials

Clinical trial condition

Diabetes Mellitus, Type 2

Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.

2,679 public trials 155 recruiting studies
Refine in advanced search Browse all conditions

Diabetes Mellitus, Type 2 trial results

Completed

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

NCT01720446

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Birmingham, Alabama, United States
  • Novo Nordisk Investigational Site Birmingham, Alabama, United States
  • Novo Nordisk Investigational Site Chandler, Arizona, United States
  • Novo Nordisk Investigational Site Anaheim, California, United States
View all 253 locations
View Trial Details
Completed

A Study of LY2881835 in Healthy People and People With Diabetes

NCT01358981

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Singapore
View Trial Details
Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

NCT01885208

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Anniston, Alabama, United States
  • Novo Nordisk Investigational Site Birmingham, Alabama, United States
  • Novo Nordisk Investigational Site Pell City, Alabama, United States
  • Novo Nordisk Investigational Site Glendale, Arizona, United States
View all 146 locations
View Trial Details
Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

NCT01930188

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Buenos Aires, Argentina
  • Novo Nordisk Investigational Site CABA, Argentina
  • Novo Nordisk Investigational Site CABA, Argentina
  • Novo Nordisk Investigational Site Mar del Plata, Argentina
View all 141 locations
View Trial Details
Completed

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

NCT02128932

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Birmingham, Alabama, United States
  • Novo Nordisk Investigational Site Ozark, Alabama, United States
  • Novo Nordisk Investigational Site Tuscumbia, Alabama, United States
  • Novo Nordisk Investigational Site Gilbert, Arizona, United States
View all 231 locations
View Trial Details

Related conditions